SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-027958
Filing Date
2024-03-07
Accepted
2024-03-07 16:12:12
Documents
13
Period of Report
2024-03-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K virx-20240301.htm   iXBRL 8-K 44572
2 EX-99.1 virx-ex99_1.htm EX-99.1 155119
  Complete submission text file 0000950170-24-027958.txt   324750

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20240301.xsd EX-101.SCH 23862
15 EXTRACTED XBRL INSTANCE DOCUMENT virx-20240301_htm.xml XML 4543
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 24730220
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)